Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared a post on X about a recent paper by Hussein Tawbi et al. published in JCO:
“The 3-year results of RELATIVITY 047 out in Journal of Clinical Oncology.
Nivolumab and relatlimab continues to impress. Toxicity profile better than nivo ipi. Interestingly, at the 3 year follow up, upper bound of HR 95% ci is less than 1 for overall survival.”
Authors: Hussein Tawbi et al.
More posts featuring Akhil Santhosh.
